Phase I study of the LSD1 inhibitor tranylcypromine (TCP) in combination   with all-trans retinoic acid (ATRA) and low-dose cytarabine (LDAC) in   elderly, medically non-fit patients with AML or high-risk MDS (TRANSATRA   trial)

Title:: Phase I study of the LSD1 inhibitor tranylcypromine (TCP) in combination with all-trans retinoic acid (ATRA) and low-dose cytarabine (LDAC) in elderly, medically non-fit patients with AML or high-risk MDS (TRANSATRA trial)
Document type:: Meeting Abstract
Author(s):: Kruszewski, M.; Schmoor, C.; Berg, T.; Schittenhelm, M.; Goetze, K.; Kuendgen, A.; Pabst, C.; Ma, T.; Frey, A.; Moschalski, K.; Rehman, U-U; Jung, J.; Duyster, J.; Jung, M.; Schuele, R.; Waesch, R.; Grishina, O.; Lubbert, M.
Journal title abbreviation:: Oncology Research and Treatment
Year:: 2023
Journal volume:: 46 Suppl 5
Pages contribution:: 101-101
Print-ISSN:: 2296-5270
TUM Institution:: Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)
BibTeX

Occurrences: